ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Historical Holders from Q3 2020 to Q2 2025

Symbol
ALXO on Nasdaq
CUSIP
00166B105
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
54.6M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
29.1M
Holdings value
$12.6M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
60
Number of buys
18
Number of sells
-64
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 8.5% $4.78M 4.64M Redmile Group, LLC Jun 30, 2025
HBM Healthcare Investments (Cayman) Ltd. 8.4% +27.1% $2.21M $526K 4.5M +31.3% HBM Healthcare Investments (Cayman) Ltd. Mar 31, 2025
TANG CAPITAL PARTNERS LP 6.3% $1.62M 3.3M TANG CAPITAL MANAGEMENT, LLC Dec 31, 2024
TANG CAPITAL MANAGEMENT LLC 5.9% $1.55M 3.16M TANG CAPITAL MANAGEMENT, LLC Mar 31, 2025
FMR LLC 3.4% $881K 1.8M FMR LLC Nov 29, 2024

Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q2 29.1M $12.6M -$2.79M $0.42 60
2025 Q1 34.8M $21.7M -$4.3M $0.62 83
2024 Q4 41M $68.5M -$8.51M $1.67 85
2024 Q3 45.5M $83.1M -$40.3M $1.82 92
2024 Q2 48.5M $292M -$2.81M $6.03 109
2024 Q1 45.8M $510M -$4.93M $11.15 104
2023 Q4 35.7K $531K +$531K $14.89 2
2023 Q3 33.3M $160M -$6.35M $4.80 76
2023 Q2 34.3M $257M -$6.38M $7.51 74
2023 Q1 35.7M $161M -$6M $4.52 85
2022 Q4 36.4M $411M -$2.05M $11.27 86
2022 Q3 36M $345M +$5.89M $9.57 93
2022 Q2 35.5M $287M -$17M $8.09 90
2022 Q1 36.8M $622M +$3.01M $16.90 93
2021 Q4 36.3M $779M -$56.1M $21.49 101
2021 Q3 34.5M $2.55B +$109M $73.86 111
2021 Q2 33.3M $1.82B -$28M $54.68 101
2021 Q1 32.2M $2.37B +$120M $73.74 90
2020 Q4 30.5M $2.63B +$420M $86.20 85
2020 Q3 27.3M $1.03B +$1.03B $37.74 56